Militants attack Pakistan checkpoint in Balochistan, killing 7 soldiers

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. KARACHI: At least seven Pakistani soldiers were killed in a terrorist attack in the country's restive Balochistan province, the Army said on Sunday.The militants fire-raided a Frontier Corps (FC) outpost in Harnai region of the province late last night, it said.During the intense exchange of fire, seven soldiers were killed, it said.The area was cordoned off and escape routes blocked to apprehend the fleeing militants, while a large-scale search and clearance operation was underway."Such cowardly acts by inimical elements backed by anti-state forces will not be allowed to sabotage hard earned peace and prosperity in Balochistan," the Army said.Commenting on the attack, Prime Minister Imran Khan said that he was "saddened" over the loss of lives."My heartfelt condolences & prayers go to their families," he said.The attack followed the killing of 10 terrorists by the security forces five days ago in the province.Terrorists and militants belonging to separatist groups frequently launch attacks on security forces and civilians working on the China-Pakistan Economic Corridor projects in the province.In October, seven Frontier Corps soldiers and as many civilian guards employed by the Oil and Gas Development Company Limited (OGDCL) were killed in an armed attack on their convoy in Gwadar district. To keep reading about Militants attack Pakistan checkpoint in Balochistan, killing 7 soldiers, Click on the link. Seoul, Korea
http://dlvr.it/RpRJGF

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint